Skip to main content
Slideshow of doctors

GORE® VIABAHN® Device family

Join the next generation of care in the treatment of aortoiliac occlusive disease

The  GORE® VIABAHN® Device family of covered stent grafts offers the flexibility and conformability to safely and confidently address even the most complex cases.1,2†

Complex aortoiliac occlusive disease (AIOD) can be challenging to treat. For TASC II C and D lesions, guidelines recommend surgery, although multiple consensus and practice guidelines now generally endorse an endovascular-first strategy in experienced endovascular centers.3-6 Covered stents offer promising advantages over bare metal stents.1,7,8 The GORE® VIABAHN® Device family is at the forefront of this next generation of care.

When to consider covered stents:

*As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS Heparin Surface.

†The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis indication includes de novo or restenotic lesions in iliac arteries, including those at the aortic bifurcation. The GORE® VIABAHN® Endoprosthesis indication includes lesions in the iliac arteries only. See product indications.

  1. Piazza M, Squizzato F, Dall'Antonia A, et al.  Outcomes of self expanding PTFE covered stent versus bare metal stent for chronic iliac artery occlusion in matched cohorts using propensity score modelling.  European Journal of Vascular & Endovascular Surgery 2017;54(2):177-185.
  2. Panneton JM, Bismuth J, Gray BH, Holden A.  Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy 2020;27(5):728-736.
  3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group.  Inter-Society consensus for the management of peripheral arterial disease (TASC II).  Journal of Vascular Surgery 2007;45(1)Supplement S:S5-S67.
  4. Klein AJ, Feldman DN, Aronow HD, et al; Peripheral Vascular Disease Committee for the Society for Cardiovascular Angiography and Interventions.  SCAI expert consensus statement for aorto-iliac arterial intervention appropriate use.  Catheterization & Cardiovascular Interventions 2014;84(4):520-528.  
  5. Rossi M, Iezzi R. Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovascular & Interventional Radiology 2014;37(1):13-25. 
  6. European Stroke Organisation, Tendera M, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).  European Heart Journal 2011;32(22):2851-2906.
  7. Mwipatayi BP, Sharma S, Daneshmand A, et al; COBEST co-investigators. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. Journal of Vascular Surgery 2016;64(1):83-94.e1.
  8. Sabri SS, Choudhri A, Orgera G, et al. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation.  Journal of Vascular & Interventional Radiology 2010;21(7):995-1003.

eIFU Symbol

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly